CNV-2197944 (Neuropathic Pain) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 86 Pages
|CNV-2197944(神經病變性疼痛治療藥):市場預測與分析 CNV-2197944 (Neuropathic Pain) - Forecast and Market Analysis to 2022|
|出版日期: 2014年04月30日||內容資訊: 英文 86 Pages||
CNV-2197944是Convergence Pharmaceuticals針對慢性疼痛所開發的新治療藥。目前正針對糖尿病疼痛性神經病變(PDN)及帶狀皰疹後神經痛(PHN)治療藥，進行到臨床實驗第二階段。GlaxoSmithKline(GSK)在取得Convergence Pharmaceuticals18%的股權時，作為條件由GSK方簽下收購CNV-2197944的契約，但在2011年卻以Pharmaceuticals重組的一環讓給了子公司Calchan Ltd.，目前由該公司保有該藥劑的所有權。
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
CNV-2197944 is a novel therapy being developed by Convergence Pharmaceuticals for the treatment of chronic pain. It is currently in Phase II of clinical development for both PHN and PDN. The drug was acquired from GlaxoSmithKline (GSK) in 2010 as part of an agreement in which GSK acquired an 18% minority equity stake in Convergence Pharmaceuticals. However, as part of the restructuring of Convergence in 2011, CNV-2197944 was transferred to Calchan Ltd., a sister company of Convergence Pharmaceuticals, which now holds the proprietary rights to CNV-2197944.